| Management target | Revenue 25.0% FY27-29 |
|---|
| Revenue growth | Consolidated -19.2% YoY; Innoxel +165%; VHPL +52%. |
|---|---|
| Margins | Gross margins up 1,000 bps; EBITDA margin currently 9.1%. |
| Order book | ₹171 Cr (Tenders ₹119 Cr, Exports ₹33 Cr, Intl ₹20 Cr). |
| Demand visibility | Strong order book of ₹171 Cr for standalone BPL. |
| Management confidence | High on subsidiary scaling and margin normalization. |
Growth
Subsidiaries Innoxel (+165% YoY) and Varenyam Healthcare (+52% YoY) drove growth, now contributing 46% of gross revenue.
Outlook
Management guides Innoxel revenue of ₹70-90 Cr for FY27 and EBITDA break-even; targeting US/EU CDMO scaling.
Risks
Consolidated EBITDA decline driven by increased operating expenses and Innoxel's ₹(10.4) Cr loss pre-breakeven.
Investor Presentation filed with BSE, BSE: 541096. Summary written with AI assistance from the document.
Bharat Parenterals Ltd: key numbers
- Share price
- ₹1,842.35
- Market cap
- ₹1,270 Cr
- Revenue (annual)
- ₹345.4 Cr
- Net profit (annual)
- ₹-8.19 Cr
- P/E (TTM)
- -82.4×Sector 47.4×
- Promoter holding
- 67.20%+0.03% QoQ
- FII holding
- 0.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bharat Parenterals Ltd
All →Bharat Parenterals Board Meeting Date
Bharat Parenterals intimated that its Board will meet on 29 September 2026 to consider a preferential equity issue. The agenda item is proposed, not yet approved, with no amount disclosed.
Bharat Parenterals Management Change
Bharat Parenterals Limited has re-appointed Mr. Hemang Jayendrabhai Shah as Executive Director for a 5-year term effective July 2, 2026.
Bharat Parenterals Annual General Meeting
Bharat Parenterals Limited held its 33rd Annual General Meeting on September 19, 2026. The proceedings covered the adoption of financial statements and various resolutions.
Bharat Parenterals Dividend
Bharat Parenterals Limited has fixed September 12, 2026, as the record date to determine shareholder eligibility for the dividend for FY 2025-26.
Bharat Parenterals Annual Report
Bharat Parenterals Limited has submitted its Annual Report for the financial year 2025-26. The report includes the notice for the 33rd Annual General Meeting.
Bharat Parenterals Annual General Meeting
Bharat Parenterals Limited has scheduled its 33rd Annual General Meeting on September 19, 2026, to discuss financial results, dividend declaration, and director reappointments.